Table 4.

HRs for breast cancer mortality stratified by stage and major breast cancer subtypes (N = 934)

Alive orDied ofUnivariate HRAdjusted HRa
Died of Other CausesBreast Cancer(95% CI)(95% CI)
All stages
 Luminal A4901281.001.00
 Luminal B25152.01 (1.18–3.42)1.96 (1.08–3.54)
 Basal Like157521.30 (0.94–1.79)1.20 (0.80–1.82)
 HER2-enriched41262.39 (1.57–3.64)2.56 (1.53–4.29)
Stage 1
 Luminal A316301.001.00
 Luminal B1232.38 (0.73–7.81)7.39 (1.72–31.77)
 Basal Like72101.37 (0.67–2.79)1.61 (0.54–4.81)
 HER2-enriched1542.90 (1.02–8.26)6.62 (1.78–24.57)
Stage 2
 Luminal A156651.001.00
 Luminal B1291.84 (0.92–3.69)2.23 (1.01–4.96)
 Basal Like78291.06 (0.68–1.64)1.22 (0.71–2.11)
 HER2-enriched25121.26 (0.68–2.33)1.85 (0.89–3.85)
Stage 3–4
 Luminal A18331.001.00
 Luminal B131.37 (0.42–4.48)0.76 (0.17–3.39)
 Basal Like7131.49 (0.78–2.84)0.94 (0.31–2.86)
 HER2-enriched1103.47 (1.68–7.19)1.11 (0.25–4.89)

NOTE: 7 dichotomous variables were created to represent 8 breast cancer treatment categories:

(i) surgery+radiation+chemotherapy+tamoxifen; (ii) surgery+radiation+chemotherapy; (iii) surgery+radiation+tamoxifen; (iv) surgery+ chemotherapy+tamoxifen; (v) surgery+radiation; (vi) surgery+chemotherapy; (vii) surgery+ tamoxifen; (viii) surgery only.

  • aHRs are adjusted for age at diagnosis, years of first breast cancer diagnosis, menopausal status, lymph node status, stage at diagnosis, and treatment regimens.